Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects

Susan M. Pond, Theodore G Tong, Neal L. Bertowitz, Peyton Jacob, Jean Rigod

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Plasma concentrations and urinary excretion of meperidine and its metabolite normeperidine were determined after intravenous and oral administration to II men; five men had hepatic cirrohosis and six were normal. Systemic clearance of meperidine was smaller and bioavailability and half-life greater in the cirrhotic patients than in the normal subjects. Plasma concentrations and 24-hr urinary excretion of normeperidine was lower and persistence of normeperidine in plasma longer in the patients with cirrhosis. The route of administration did not alter the fraction of normeperidine generated from meperidine. The results suggest that in patients requiring repeated meperidine dosage the drug should be taken parenterally rather than orally to allow maximal analgesia and minimal formation of normeperidine. Patients with cirrhosis may be relatively protected from normeperidine toxicity because of impaired formation, but the risk of cumulative toxicity may be greater than in normal subjects because of slower elimination of the metabolite and greater sensitivity to the effects of narcotics on the central nervous system.

Original languageEnglish (US)
Pages (from-to)183-188
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume30
Issue number2
StatePublished - Aug 1981
Externally publishedYes

Fingerprint

Meperidine
Fibrosis
Narcotics
Intravenous Administration
Analgesia
Biological Availability
Oral Administration
Half-Life
normeperidine
Central Nervous System
Liver
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. / Pond, Susan M.; Tong, Theodore G; Bertowitz, Neal L.; Jacob, Peyton; Rigod, Jean.

In: Clinical Pharmacology and Therapeutics, Vol. 30, No. 2, 08.1981, p. 183-188.

Research output: Contribution to journalArticle

Pond, Susan M. ; Tong, Theodore G ; Bertowitz, Neal L. ; Jacob, Peyton ; Rigod, Jean. / Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. In: Clinical Pharmacology and Therapeutics. 1981 ; Vol. 30, No. 2. pp. 183-188.
@article{6d7678aec3584ae6bc7e987ed1a05a08,
title = "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects",
abstract = "Plasma concentrations and urinary excretion of meperidine and its metabolite normeperidine were determined after intravenous and oral administration to II men; five men had hepatic cirrohosis and six were normal. Systemic clearance of meperidine was smaller and bioavailability and half-life greater in the cirrhotic patients than in the normal subjects. Plasma concentrations and 24-hr urinary excretion of normeperidine was lower and persistence of normeperidine in plasma longer in the patients with cirrhosis. The route of administration did not alter the fraction of normeperidine generated from meperidine. The results suggest that in patients requiring repeated meperidine dosage the drug should be taken parenterally rather than orally to allow maximal analgesia and minimal formation of normeperidine. Patients with cirrhosis may be relatively protected from normeperidine toxicity because of impaired formation, but the risk of cumulative toxicity may be greater than in normal subjects because of slower elimination of the metabolite and greater sensitivity to the effects of narcotics on the central nervous system.",
author = "Pond, {Susan M.} and Tong, {Theodore G} and Bertowitz, {Neal L.} and Peyton Jacob and Jean Rigod",
year = "1981",
month = "8",
language = "English (US)",
volume = "30",
pages = "183--188",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects

AU - Pond, Susan M.

AU - Tong, Theodore G

AU - Bertowitz, Neal L.

AU - Jacob, Peyton

AU - Rigod, Jean

PY - 1981/8

Y1 - 1981/8

N2 - Plasma concentrations and urinary excretion of meperidine and its metabolite normeperidine were determined after intravenous and oral administration to II men; five men had hepatic cirrohosis and six were normal. Systemic clearance of meperidine was smaller and bioavailability and half-life greater in the cirrhotic patients than in the normal subjects. Plasma concentrations and 24-hr urinary excretion of normeperidine was lower and persistence of normeperidine in plasma longer in the patients with cirrhosis. The route of administration did not alter the fraction of normeperidine generated from meperidine. The results suggest that in patients requiring repeated meperidine dosage the drug should be taken parenterally rather than orally to allow maximal analgesia and minimal formation of normeperidine. Patients with cirrhosis may be relatively protected from normeperidine toxicity because of impaired formation, but the risk of cumulative toxicity may be greater than in normal subjects because of slower elimination of the metabolite and greater sensitivity to the effects of narcotics on the central nervous system.

AB - Plasma concentrations and urinary excretion of meperidine and its metabolite normeperidine were determined after intravenous and oral administration to II men; five men had hepatic cirrohosis and six were normal. Systemic clearance of meperidine was smaller and bioavailability and half-life greater in the cirrhotic patients than in the normal subjects. Plasma concentrations and 24-hr urinary excretion of normeperidine was lower and persistence of normeperidine in plasma longer in the patients with cirrhosis. The route of administration did not alter the fraction of normeperidine generated from meperidine. The results suggest that in patients requiring repeated meperidine dosage the drug should be taken parenterally rather than orally to allow maximal analgesia and minimal formation of normeperidine. Patients with cirrhosis may be relatively protected from normeperidine toxicity because of impaired formation, but the risk of cumulative toxicity may be greater than in normal subjects because of slower elimination of the metabolite and greater sensitivity to the effects of narcotics on the central nervous system.

UR - http://www.scopus.com/inward/record.url?scp=0019404314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019404314&partnerID=8YFLogxK

M3 - Article

C2 - 7249503

AN - SCOPUS:0019404314

VL - 30

SP - 183

EP - 188

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -